Revenue Breakdown
Composition ()
No data
Revenue Streams
Bioventus Inc (BVS) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Pain Treatments, accounting for 48.5% of total sales, equivalent to $67.18M. Other significant revenue streams include Surgical solutions and Restorative Therapies. Understanding this composition is critical for investors evaluating how BVS navigates market cycles within the Medical Equipment, Supplies & Distribution industry.
Profitability & Margins
Evaluating the bottom line, Bioventus Inc maintains a gross margin of 66.95%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 8.73%, while the net margin is 2.89%. These profitability ratios, combined with a Return on Equity (ROE) of 6.46%, provide a clear picture of how effectively BVS converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, BVS competes directly with industry leaders such as MDXG and CBLL. With a market capitalization of $726.66M, it holds a leading position in the sector. When comparing efficiency, BVS's gross margin of 66.95% stands against MDXG's 83.76% and CBLL's 87.33%. Such benchmarking helps identify whether Bioventus Inc is trading at a premium or discount relative to its financial performance.
